Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily aspirin boost ovarian cancer treatment?

NCT ID NCT05080946

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goal is to see if aspirin makes the tumor more vulnerable to the immune system, potentially improving treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Aspirin (325 mg daily)
What this could lead to
If it works, this could point toward a way to make standard chemotherapy more effective for ovarian cancer by reducing immune suppression in the tumor.
What could go wrong
This is a very early, small pilot study (Phase 1) looking at immune markers, not survival. Aspirin may not change tumor immune features, and results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma peritoneal carcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CANCER PERITONEAL CANCER

Contacts and locations

Locations

  • Inova Schar Cancer Institute

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Oregon Health and Science University

    RECRUITING

    Portland, Oregon, 97239, United States

  • University of Virginia Comprehensive Cancer Center

    RECRUITING

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.